The U.S. Food and ​Drug Administration has ‌told Novo Nordisk to stop running ​a consumer ​ad for its blockbuster ⁠diabetes drug ​Ozempic, saying the ​commercial makes false and misleading claims about ​what the ​drug can do, according to ‌a ⁠letter dated February 26.